theory clinical_2_4
imports Main

begin

typedecl entity
typedecl event

consts
  SyntheticLethality :: "entity ⇒ bool"
  GeneticEvents :: "entity ⇒ bool"
  Loss :: "entity ⇒ bool"
  BRCA2 :: "entity ⇒ bool"
  Occurs :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  CoOccurrence :: "event ⇒ bool"
  Result :: "event ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Repair :: "event ⇒ bool"
  Through :: "entity ⇒ entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  DoubleStrandBreaks :: "entity ⇒ bool"
  SingleStrandBreakRepair :: "entity ⇒ bool"
  Cells :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Prevent :: "event ⇒ bool"
  Force :: "event ⇒ bool"
  Rely :: "event ⇒ bool"
  On :: "event ⇒ entity ⇒ bool"
  BRCA2Loss :: "entity ⇒ bool"
  Compromised :: "event ⇒ bool"
  Patients :: "entity ⇒ bool"
  Inhibition :: "entity ⇒ bool"
  PARP1 :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Mechanism :: "event ⇒ bool"
  To :: "entity ⇒ entity ⇒ bool"
  cumulativeDamage :: "entity"
  DNA :: "entity"

(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)
axiomatization where
  explanation_1: "∃x y z e1 e2 e3 e4. SyntheticLethality x ∧ GeneticEvents y ∧ Loss z ∧ BRCA2 z ∧ Occurs e1 ∧ Agent e1 x ∧ CoOccurrence e2 ∧ Agent e2 y ∧ Result e3 ∧ Agent e3 y ∧ Patient e3 cellDeath ∧ Repair e4 ∧ Agent e4 y ∧ Patient e4 DNA ∧ Through DNA multiplePathways"

(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3 e4 e5. PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z ∧ Cells w ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Force e3 ∧ Agent e3 x ∧ Patient e3 w ∧ Rely e4 ∧ Agent e4 w ∧ On e4 defectiveHomologousRecombinationRepair ∧ Repair e5 ∧ Agent e5 w ∧ Patient e5 DNA"

(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised. *)
axiomatization where
  explanation_3: "∃x y z e1 e2 e3 e4. BRCA2Loss x ∧ SyntheticLethality y ∧ Cells z ∧ Cause e1 ∧ Agent e1 y ∧ Patient e1 z ∧ Rely e2 ∧ Agent e2 z ∧ On e2 singularMechanism ∧ Repair e3 ∧ Agent e3 z ∧ Patient e3 cumulativeDNADamage ∧ Compromised e4 ∧ Agent e4 primaryRepairPathways"

theorem hypothesis:
  assumes asm: "Patients x ∧ Loss y ∧ BRCA2 y ∧ Inhibition z ∧ PARP1 z ∧ SyntheticLethality w"
  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)
  shows "∃x y z w e1 e2 e3 e4. Patients x ∧ Loss y ∧ BRCA2 y ∧ Inhibition z ∧ PARP1 z ∧ SyntheticLethality w ∧ Benefit e1 ∧ Agent e1 x ∧ Patient e1 z ∧ Cause e2 ∧ Agent e2 w ∧ Patient e2 y ∧ Rely e3 ∧ Agent e3 y ∧ Mechanism e3 ∧ Repair e4 ∧ Agent e4 y ∧ Patient e4 cumulativeDamage ∧ To cumulativeDamage DNA"
proof -
  (* From the premise, we have known information about patients, loss of BRCA2, PARP1 inhibition, and synthetic lethality. *)
  from asm have "Patients x ∧ Loss y ∧ BRCA2 y ∧ Inhibition z ∧ PARP1 z ∧ SyntheticLethality w" by simp
  (* Explanation 3 states that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)
  (* This aligns with the logical relation Implies(And(B, J), I), where B is loss of BRCA2 and J is primary repair pathways are compromised. *)
  (* We can infer that cells rely on a singular mechanism to repair cumulative DNA damage. *)
  then have "Rely e3 ∧ Agent e3 y ∧ Mechanism e3 ∧ Repair e4 ∧ Agent e4 y ∧ Patient e4 cumulativeDamage ∧ To cumulativeDamage DNA" sledgehammer
  (* The hypothesis states that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)
  (* We can conclude that there is a benefit to patients from PARP1 inhibition. *)
  then have "Benefit e1 ∧ Agent e1 x ∧ Patient e1 z" <ATP>
  then show ?thesis <ATP>
qed

end
